IGLON5 and blood coagulation disease: Five (4.8%) patients could not be clearly classified based on ASFA recommendations (polytrauma-associated coagulopathy, anti-IgLON5-associated encephalopathy, polyradiculoneuritis, acute demyelinating neuropathy, autoimmune encephalitis) (Table 2).